Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

siRNA Transfection

DH Debasish Halder
SJ Su-Jin Jeon
JY Ji-Yong Yoon
JL Jeong-Ju Lee
SJ Soo Young Jun
MC Min-Hyuk Choi
BJ Bohyeon Jeong
DS Duk Hyun Sung
DL Da Yong Lee
BK Byoung Joon Kim
NK Nam-Soon Kim
request Request a Protocol
ask Ask a question
Favorite

Small interfering RNA (siRNA) sequences against TREX1 and ERO1α were purchased from Bioneer, Daejeon, Republic of Korea, and control sequences were purchased from ST Pharm (Seoul, Republic of Korea). Then, 50–100 nM of each siRNA was transfected using the Lipofectamine RNAiMAX reagent (Invitrogen, CA, USA; 13,778,150) following the manufacturer’s instructions. The siRNA sequences were as follows: siCon sense: 5′-AUG AAC GUG AAU UGC UCA ATT-3′, antisense: 5′-UUG AGC AAU UCA CGU UCA UTT-3′; siTREX1 sense: 5′-GACCAAGCCAAGACCAUCU-3′, antisense: 5′-AGAUGGUCUUGGCUUGGUC-3′; and siERO1α sense: 5′-CACUCAAGGAGAGUCAUCU-3′, antisense: 5′-AGAUGACUCUCCUUGAGUG-3′.

Copyright and License information: The Author(s) ©2021
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A